Capital One Financial Weighs in on Chimerix, Inc.’s FY2028 Earnings (NASDAQ:CMRX)

Chimerix, Inc. (NASDAQ:CMRX) – Capital One Financial reduced their FY2028 earnings per share (EPS) estimates for Chimerix in a research note issued on Wednesday, May 1st. Capital One Financial analyst N. Quibria now expects that the biopharmaceutical company will earn $0.07 per share for the year, down from their previous estimate of $0.13. The consensus estimate for Chimerix’s current full-year earnings is ($0.77) per share.

A number of other research firms have also commented on CMRX. StockNews.com lowered shares of Chimerix from a “hold” rating to a “sell” rating in a research note on Friday. Wedbush reiterated an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a research report on Monday, February 12th. Finally, HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research report on Friday, March 1st.

Chimerix Stock Performance

CMRX stock opened at $0.95 on Friday. The firm’s 50-day moving average is $1.04 and its two-hundred day moving average is $1.00. The company has a market capitalization of $85.41 million, a price-to-earnings ratio of -1.02 and a beta of 1.13. Chimerix has a 52 week low of $0.88 and a 52 week high of $1.57.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Chimerix had a negative return on equity of 39.62% and a negative net margin of 25,337.96%. During the same quarter last year, the company posted ($0.24) earnings per share.

Institutional Investors Weigh In On Chimerix

Several large investors have recently modified their holdings of the stock. Vance Wealth Inc. acquired a new stake in shares of Chimerix during the fourth quarter worth $46,000. Pale Fire Capital SE purchased a new stake in Chimerix during the third quarter valued at about $95,000. Assenagon Asset Management S.A. increased its position in shares of Chimerix by 167.3% in the third quarter. Assenagon Asset Management S.A. now owns 426,672 shares of the biopharmaceutical company’s stock worth $410,000 after acquiring an additional 267,044 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Chimerix by 190.0% during the third quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock valued at $568,000 after acquiring an additional 387,638 shares during the period. Finally, Vestal Point Capital LP purchased a new stake in shares of Chimerix in the 4th quarter valued at approximately $1,348,000. 45.42% of the stock is owned by institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.